Cardiovascular Diabetology · 2009 · 46 citations · 36 references
MedicineEndocrinologyInternal MedicineCardiovascular PharmacotherapyDiabetologyRenal PathophysiologyCardiovascular DiseaseDiabetes MellitusDiabetic NephropathyEndothelial ActivationEndothelial DysfunctionMicrovascular Dysfunction AssessmentEndothelial Activation MarkersEndothelial Adhesion MoleculesEndothelial Dysfunction AssessmentEndothelial Function AssessmentEndothelial Nitric Oxide Synthase DysfunctionLeukocyte Adhesion MoleculesRenal Function CovariatesVascular Endothelial Dysfunction
BACKGROUND: Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial nitric oxide synthase (eNOS) that is associated with endothelial dysfunction, and is a risk marker for cardiovascular disease, a significant problem in Type 1 diabetes. The aim of the present study was to measure circulating ADMA, and define its association with endothelial dysfunction and endothelial markers in people with Type 1 diabetes with low likelihood of macrovascular disease. METHODS: Sixty-one young people with Type 1 diabetes without macrovascular disease or nephropathy and 62 healthy volunteers underwent brachial artery flow-mediated dilatation (FMD) and assay of plasma ADMA and adhesion molecules. RESULTS: Age, gender, BMI, lipid profile and renal function were similar in the two groups. People with Type 1 diabetes had impaired FMD compared to healthy controls (5.0 +/- 0.4 vs 8.9 +/- 0.4%; p < 0.001). Plasma ADMA levels were significantly lower in the people with diabetes compared to healthy controls (0.52 +/- 0.12 vs 0.66 +/- 0.20 micromol/l, p < 0.001). Plasma ICAM-1, E-selectin and PAI-1 levels were significantly higher in people with diabetes compared to healthy controls (median 201 (IQR 172-226) vs 180 (156-216) microg/l, p = 0.027; 44.2 (32.6-60.9) vs. 33.1 (22.4-51.0) microg/l; p = 0.003 and 70.8 (33.3-85.5) vs 46.3 (23.9-76.8) microg/l, p = 0.035). Plasma ADMA and VCAM-1 levels were positively correlated (r = 0.37, p = 0.003) in people with diabetes. There was no correlation between the plasma ADMA and FMD. CONCLUSION: ADMA levels are not associated with endothelial dysfunction in young adults with Type 1 diabetes without microalbuminuria or known macrovascular disease. This suggests that the impaired endothelial function in these individuals is not a result of eNOS inhibition by ADMA.
36
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
A. Leone, S. Moncada, Patrick Vallance et al. · The Lancet · 1992 · 2.1K citations
Medicine, Nephrology, Pharmacology +11
Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction
Rainer H. Böger, Stefanie M. Bode‐Böger, Andrzej Szuba et al. · Circulation · 1998 · 1.2K citations · Full text
Medicine, Cardiology, Pharmacology +12
Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus
Ulrich Hink, Huige Li, Hanke Mollnau et al. · Circulation Research · 2001 · 1.2K citations
Medicine, Biochemistry, Pharmacology +16